Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
EGFR Antagonists in Cancer Treatment
2008 Standout
Pancreatic cancer
2004 Standout
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
2001
Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations
2003
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
2004
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
EMT and Dissemination Precede Pancreatic Tumor Formation
2012 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
2006 Standout
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Lung Cancer
2008 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Rhabdomyolysis and Acute Kidney Injury
2009 Standout
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
2007 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
2002
Lung cancer: current therapies and new targeted treatments
2016 Standout
Cancer genes and the pathways they control
2004 Standout
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
2014
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer
2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
2010
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
The effect of symptom clusters on functional status and quality of life in women with breast cancer
2009
Gastric cancer
2020 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Role of gemcitabine in cancer therapy
2005
Microtubules as a target for anticancer drugs
2004 Standout
Pancreatic Cancer
2010 Standout
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC
2004
Interleukin-2: Clinical applications
2002
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial
2002 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group
2005
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
2007
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
2015
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
2006
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
2007
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
2003
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Systematic review: The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence
1997
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
1992 Standout
Cytokine Storm
2020 Standout
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
2002
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
2003
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
2008
Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
2011 StandoutNobel
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
2002
Works of Elide Matano being referenced
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
2005
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study
2000
Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration
1998
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer
1991
Low-dose dopamine induces early recovery of recombinant interleukin-2—Impaired renal function
1993
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002